SPECTRILA

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, UK.

Active ingredients

The drug SPECTRILA contains one active pharmaceutical ingredient (API):

1	L-asparagine-amidohydrolase UNII G4FQ3CKY5R - ASPARAGINASE
	Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells.
	Read more about Asparaginase

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX02	Asparaginase	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	559119070009007, 559119070009107
EE	Ravimiamet	1708691, 1708703
FR	Base de données publique des médicaments	66242506
GB	Medicines & Healthcare Products Regulatory Agency	329204
IT	Agenzia del Farmaco	044700019, 044700021
LT	Valstybinė vaistų kontrolės tarnyba	1079268, 1079269
NL	Z-Index G-Standaard, PRK	38563
PL	Rejestru Produktów Leczniczych	100363024
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62603001, W62603002